The filing is a routine scientific update with no new financial data or guidance. The IND timeline for CG923308 (Q1 2027) is consistent with prior disclosures. Monitor for IND acceptance and Phase 1 trial initiation as the next catalysts.
Price Chart
Executive Summary
Gyre Therapeutics filed an 8-K furnishing an investor presentation under Item 7.01, to be presented at a scientific conference in Shanghai on May 15, 2026. The presentation highlights the company's pipeline, including the recently announced acquisition of Cullgen, and provides preclinical data on its lead degrader candidate CG923308, which targets CDK2-Cyclin E for solid cancers. The company anticipates submitting an IND for CG923308 in the first quarter of 2027.
Key Facts
- Presentation furnished as Exhibit 99.1, to be presented at a scientific conference in Shanghai on May 15, 2026.
- Pipeline includes marketed product ETUARY (pirfenidone) for IPF and multiple preclinical/clinical candidates for fibrosis, inflammatory diseases, and cancer.
- Lead degrader candidate CG923308 (CDK2-Cyclin E degrader) is in IND-enabling studies; IND submission anticipated in Q1 2027.
- Preclinical data shows CG923308 induces potent and selective CDK2-Cyclin E degradation, cell senescence, and growth inhibition in CCNE1-amplified solid tumors and CDK4/6i-resistant breast cancer models.
- CG923308 demonstrated superiority over Phase 2/3 CDK2 inhibitors in vitro and in vivo, and is orally bioavailable across preclinical species.
- Company has ~740 employees worldwide, with operations in San Diego, Shanghai, and Beijing.
- No financial guidance or preliminary financial results were disclosed in the filing.
Financial Impact
No financial figures disclosed; filing is a routine investor presentation with no material financial data.
Risk Factors
- CG923308 is in preclinical/IND-enabling stage; clinical failure or regulatory delays are significant risks.
- The company's reliance on China operations introduces geopolitical and regulatory risks.
- No financial data provided; the company's cash runway and ability to fund operations are not addressed in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-021360 |
| Document: ef20073544_8k.htm | 0001140361-26-021360 |
| Document: 0001140361-26-021360-index-headers.html | 0001140361-26-021360 |
| Document: 0001140361-26-021360-index.html | 0001140361-26-021360 |
| Document: 0001140361-26-021360.txt | 0001140361-26-021360 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $5.85 | awaiting T+20 | — | $6.37 (+8.91%) |
Sep 1, 2026 8w ago | 8-K | $6.47 $7.35 | ▲ +13.52% | ▲ +12.34% | $6.37 (−1.52%) |
Aug 26, 2026 8w ago | 8-K | $6.65 $7.43 | ▲ +11.73% | ▲ +10.53% | $6.37 (−4.19%) |
Aug 7, 2026 11w ago | 8-K | $6.67 $6.86 | ▼ −2.85% | ▼ −3.25% | $6.37 (+4.48%) |
Aug 4, 2026 12w ago | EFFECT | $6.15 $6.47 | ▲ +5.20% | ▲ +6.44% | $6.37 (+3.60%) |
Jul 13, 2026 15w ago | S-3/A | $6.34 $6.64 | ▲ +4.73% | ▲ +2.24% | $6.37 (+0.50%) |
Jun 2, 2026 21w ago | 8-K | $5.56 $6.52 | ▲ +17.27% | ▲ +18.83% | $6.37 (+14.60%) |
May 14, 2026 23w ago | 8-K | $6.55 $5.86 | ▼ −10.53% | ▼ −12.65% | $6.37 (−2.73%) |
May 4, 2026 25w ago | 8-K / DEFA14A | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.37 (−19.55%) |
May 4, 2026 25w ago | Press Release | $7.92 $5.81 | ▼ −26.64% | ▼ −32.29% | $6.37 (−19.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers